This essay argues that the use of stem cells from umbilical cord blood is a business that is based on weighing the potential medical benefits for patients against the economic benefits for the company. The author interviewed all the Catalan hospitals with neonatal units, enabling them to analyze the differences between public and private institutions. The essay also provides a historical, scientific, legal and ethical perspective on the issue, enabling readers to form their own opinion in this regard.